Model-based comparative pharmacoeconomic analyses of bimatoprost 0.03% in the treatment of glaucoma or ocular hypertension in adult patients in Austria and Finland

被引：2
|
作者：
Poulsen, PB
Christensen, TL
Holmstrom, S
Buchholz, P
Walt, JG
机构：
[1] MUUSMANN Res & Consulting, Kolding, Denmark
[2] Allergan Pharmaceut Inc, Mougins, France
[3] Allergan Pharmaceut Inc, Ettlingen, Germany
[4] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)63949-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：239 / 239
页数：1
相关论文
共 46 条
  • [21] Challenges for model-based economic evaluations of glaucoma and ocular hypertension treatments
    Althin, R
    Dhawan, R
    Grima, D
    Bernard, L
    VALUE IN HEALTH, 2003, 6 (06) : 801 - 802
  • [22] Estimated Comparative Costs of Achieving a 20% Reduction in Intraocular Pressure with Bimatoprost or Latanoprost in Patients with Glaucoma or Ocular Hypertension
    Richard Fiscella
    John Walt
    Drugs & Aging, 2006, 23 : 39 - 47
  • [23] Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension
    Fiscella, R
    Walt, J
    DRUGS & AGING, 2006, 23 (01) : 39 - 47
  • [24] Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
    Wang, Kaidi
    Xu, Li
    Yuan, Zhilan
    Yao, Ke
    Zhao, Junmei
    Xu, Liang
    Fang, Aiwu
    Zhang, Mingzhi
    Wu, Lingling
    Ji, Jian
    Hou, Jiamin
    Liu, Qing
    Sun, Xinghuai
    BMC OPHTHALMOLOGY, 2014, 14
  • [25] Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
    Kaidi Wang
    Li Xu
    Zhilan Yuan
    Ke Yao
    Junmei Zhao
    Liang Xu
    Aiwu Fang
    Mingzhi Zhang
    Lingling Wu
    Jian Ji
    Jiamin Hou
    Qing Liu
    Xinghuai Sun
    BMC Ophthalmology, 14
  • [26] Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
    Xinghuai Sun
    Ke Yao
    Qinghuai Liu
    Hong Zhang
    Xiaoli Xing
    Aiwu Fang
    Xuanchu Duan
    Minbin Yu
    Michelle Y. Chen
    Jingyuan Yang
    Margot L. Goodkin
    Ophthalmology and Therapy, 2023, 12 : 341 - 353
  • [27] Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
    Sun, Xinghuai
    Yao, Ke
    Liu, Qinghuai
    Zhang, Hong
    Xing, Xiaoli
    Fang, Aiwu
    Duan, Xuanchu
    Yu, Minbin
    Chen, Michelle Y.
    Yang, Jingyuan
    Goodkin, Margot L.
    OPHTHALMOLOGY AND THERAPY, 2023, 12 (01) : 341 - 353
  • [28] Patient- and Physician-Reported Satisfaction Following Treatment With Bimatoprost 0.01% or Vehicle in Patients With Glaucoma or Ocular Hypertension (OHT)
    Craven, E. R.
    Lin, T.
    Mundorf, T.
    Tepedino, M.
    Frenkel, R.
    Walt, J.
    Liu, C. -C.
    Batoosingh, A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [29] Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension - An evidence-based review
    Olthoff, CMG
    Schouten, JSAG
    van de Borne, BW
    Webers, CAB
    OPHTHALMOLOGY, 2005, 112 (06) : 953 - 961
  • [30] An observational study of bimatoprost 0.01% in treatment-naive patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
    Nixon, Donald R.
    Simonyi, Susan
    Bhogal, Meetu
    Sigouin, Christopher S.
    Crichton, Andrew C.
    Discepola, Marino
    Hutnik, Cindy M. L.
    Yan, David B.
    CLINICAL OPHTHALMOLOGY, 2012, 6 : 2097 - 2103
12345